RXRX RECURSION PHARMACEUTICALS, INC.: institutional ownership and insider trading
360 funds reported holding $1.63B of RECURSION PHARMACEUTICALS, INC. in their latest 13F filings; in Q2 2026 funds net bought $101M, with 48 new positions and 41 funds selling out; over the last 12 months insiders bought $0 and sold $7.65M on the open market; over its last four quarters it reported revenue of $54.9M and net income of −$519M.
RXRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $7.67M, net income −$131M, EPS -0.25
- Quarter ended Mar 31, 2026: revenue $6.47M, net income −$118M, EPS -0.22
- Quarter ended Dec 31, 2025: revenue $35.5M, net income −$108M, EPS -0.17
- Quarter ended Sep 30, 2025: revenue $5.18M, net income −$162M, EPS -0.36
Famous investors holding RXRX
- Cathie Wood (ARK Investment Management): $152M, 1.0% of the portfolio
- Two Sigma (Two Sigma Investments): $12.3M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $9.32M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $6.73M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $139K, 0.0% of the portfolio
- Ray Dalio (Bridgewater Associates): $138K, 0.0% of the portfolio
Largest institutional holders of RXRX
- VANGUARD GROUP INC — $193M
- BlackRock, Inc. (BLK) — $185M
- ARK Investment Management LLC — $152M
- STATE STREET CORP (STT, STT-PG) — $127M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $114M
- BAILLIE GIFFORD & CO — $86.2M
- VANGUARD CAPITAL MANAGEMENT LLC — $83.6M
- Kinnevik AB (publ) — $65.6M
- GEODE CAPITAL MANAGEMENT, LLC — $50.7M
- SOFTBANK GROUP CORP. — $50.0M
Recent RXRX insider trades
- Oct 6, 2026: Hershberg Robert sold 25,000 shares ($125K)
- Oct 6, 2026: Borgeson Blake sold 50,000 shares ($242K)
- Sep 8, 2026: Khan Najat sold 22,408 shares ($78.9K)
- Sep 1, 2026: Borgeson Blake sold 30,000 shares ($100K)
5%+ owners
- BlackRock, Inc.: 8.5% (Schedule 13G/A, filed Jul 29, 2026)
- STATE STREET CORPORATION: 6.6% (Schedule 13G, filed Aug 7, 2026)
- Vanguard Portfolio Management: 6.0% (Schedule 13G, filed Jul 31, 2026)
- Vanguard Capital Management: 5.1% (Schedule 13G, filed Jul 31, 2026)
Who owns the most RXRX stock?
The largest institutional holders of RECURSION PHARMACEUTICALS, INC. in the latest 13F filings are VANGUARD GROUP INC ($193M), BlackRock, Inc. (BLK) ($185M), ARK Investment Management LLC ($152M).
Are insiders buying or selling RXRX?
Over the last 12 months insiders bought $0 and sold $7.65M of RECURSION PHARMACEUTICALS, INC. stock on the open market (SEC Form 4).
Which famous investors own RXRX?
Cathie Wood, Two Sigma, Ken Griffin, Izzy Englander, D. E. Shaw.
What was RXRX's revenue last quarter?
RECURSION PHARMACEUTICALS, INC. reported revenue of $7.67M for the quarter ended June 30, 2026, with net income of −$131M.
Which ETFs hold RXRX?
15 ETFs and mutual funds hold it among their top 100 positions, including XBI, ARKK, ARKG, ROBT.